Results 81 to 90 of about 1,122,477 (316)

FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications

International Journal of Pharmaceutics: X, 2019
This paper describes a new FDA’s pharmaceutical quality assessment system: Knowledge-aided Assessment & Structured Application (KASA). The KASA system is designed to: 1) capture and manage knowledge during the lifecycle of a drug product; 2) establish ...
Lawrence X. Yu, Andre Raw, Larisa Wu, Christina Capacci-Daniel, Ying Zhang, Susan Rosencrance   +5 more
doaj  

Animal and Clinical Pharmacologic Techniques in Drug Evaluation [PDF]

, 1965
John H. Nodine, PETER E. SIEGLEH
openalex   +1 more source

Multi‐omic characterization of consensus molecular subtype 1 (CMS1) colorectal cancer with dampened immune response improves precision medicine

Molecular Oncology, EarlyView.
This study highlights the importance of multi‐omic analyses in characterizing colorectal cancers. Indeed, our analysis revealed a rare CMS1 exhibiting dampened immune activation, including reduced PD‐1 expression, moderate CD8+ T‐cell infiltration, and suppressed JAK/STAT pathway.
Livia Concetti, Manuel Scimeca, Julia Bischof, Jonathan Woodsmith, Massimiliano Agostini, Cristina Fiorani, Yufang Shi, Eleonora Candi, Gerry Melino, Alessandro Mauriello, Giuseppe S. Sica   +10 more
wiley   +1 more source

Regulatory considerations for paediatric drug evaluation in China. [PDF]

BMJ Paediatr Open, 2023
Geng Y, Li Q, Sun YZ, Zhang H, Jiang YL, Wang LQ, Wu YE, Zhao W, Yang ZM.   +8 more
europepmc   +1 more source

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

Molecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker   +19 more
wiley   +1 more source

Advanced lung organoids and lung-on-a-chip for cancer research and drug evaluation: a review. [PDF]

Front Bioeng Biotechnol, 2023
Zhu L, Zhang J, Guo Q, Kuang J, Li D, Wu M, Mo Y, Zhang T, Gao X, Tan J.   +9 more
europepmc   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Evaluation of Gastric Acid as a Factor in Drug-Induced Gastric Hemorrhage in the Rat

, 1969
David A. Brodie, Barbara J. Chase
openalex   +2 more sources

Maternal use of antibiotics and cancer incidence risk in offspring: A population‐based cohort study in Manitoba, Canada

Cancer Medicine, 2019
Several epidemiological studies have found an association between maternal antibiotics use during pregnancy and increased risk of certain cancer types, although conclusions differ between studies.
Xibiao Ye, Barret A. Monchka, Christiaan H. Righolt, Salaheddin M. Mahmud   +3 more
doaj   +1 more source

Value-Based Generic Drug Evaluation Focus on Chinese Real-World Evidence. [PDF]

Int J Health Policy Manag, 2023
Lu J, Ying X, Li Z.
europepmc   +1 more source